Enhanced platelet aggregability in dogs following myocardial infarction.
Fleming
J S
JS
Pharmacology Department, Bristol Laboratories, Syracuse, NY 13201, USA.
Buyniski
J P
JP
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D002352:Carrier Proteins; D003094:Collagen / Q000494:pharmacology; D003331:Coronary Vessels / Q000601:surgery; D004176:Dipyridamole / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins / Q000494:pharmacology; D008026:Ligation; D009203:Myocardial Infarction / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology*; D011799:Quinazolines / Q000494:pharmacology; D013442:Sulfinpyrazone / Q000494:pharmacology
C439889:ASPN protein, human; D002352:Carrier Proteins; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D011799:Quinazolines; C009709:6-methyl-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-one hydrochloride; D004176:Dipyridamole; D003094:Collagen; D013442:Sulfinpyrazone